Dr. Natasha Fuksina astraMDhealth

Dr. Natasha Fuksina leads astraMDhealth in Florham Park, New Jersey, delivering telehealth-based functional medicine, obesity treatment, and hormone optimization to patients across the state. As a double board-certified physician in Internal Medicine and Obesity Medicine, Dr. Fuksina combines clinical expertise in metabolic health with advanced training in bioidentical hormone replacement therapy and peptide therapeutics. The practice operates exclusively through secure telehealth platforms, enabling New Jersey residents to access comprehensive evaluations, lab interpretation, and ongoing medical management without geographic barriers. AstraMDhealth structures care around detailed metabolic assessments, hormone panels including thyroid function and sex hormones, and individualized treatment protocols that address root causes rather than symptoms alone.

Peptide therapy at astraMDhealth targets metabolic dysfunction, body composition optimization, and age-related hormone decline through evidence-based protocols. Dr. Fuksina prescribes semaglutide and tirzepatide for patients meeting clinical criteria for obesity or metabolic syndrome, integrating these GLP-1 receptor agonists with nutritional counseling and lifestyle modification strategies. The clinic also utilizes growth hormone secretagogues such as CJC-1295 and ipamorelin for patients with documented growth hormone deficiency or those seeking body composition improvements alongside comprehensive metabolic support. Bioidentical hormone replacement therapy includes testosterone optimization for both men and women, thyroid hormone balancing with T3/T4 combinations when indicated, and estrogen/progesterone therapy tailored to individual hormone panels and symptom profiles. Each peptide and hormone protocol begins with baseline laboratory work and follows structured monitoring schedules to track efficacy and adjust dosing.

Dr. Fuksina's dual board certifications inform a clinical approach that treats obesity as a chronic disease requiring medical intervention rather than willpower alone. Her internal medicine background ensures thorough evaluation of comorbid conditions—hypertension, dyslipidemia, insulin resistance, fatty liver disease—that frequently accompany metabolic disorders. Patients receive detailed review of comprehensive metabolic panels, lipid profiles, hemoglobin A1c, insulin levels, and hormone assays during initial consultations, with Dr. Fuksina explaining how each biomarker connects to symptoms and treatment options. The practice emphasizes patient education, providing resources on peptide mechanisms of action, expected timelines for therapeutic effects, and potential side effects. Follow-up visits occur at intervals determined by treatment complexity, typically every 4-8 weeks during initial titration phases and quarterly once protocols stabilize.

The telehealth model at astraMDhealth streamlines access for New Jersey patients managing demanding schedules or mobility limitations. Video consultations allow Dr. Fuksina to conduct thorough medical histories, review symptoms, and perform visual assessments, while patients complete laboratory work at local draw stations convenient to their location. Prescriptions for peptides, bioidentical hormones, and supportive medications are sent to specialized compounding pharmacies or retail pharmacies depending on medication type. The practice coordinates with patients' primary care physicians when appropriate, sharing treatment plans and lab results to ensure continuity of care. AstraMDhealth maintains a patient portal for secure messaging, lab result access, and appointment scheduling, reducing administrative friction and enabling responsive communication between visits.

What distinguishes astraMDhealth in the New Jersey functional medicine landscape is Dr. Fuksina's integration of obesity medicine principles with hormone optimization and peptide therapeutics. Rather than offering isolated treatments, the practice addresses the interconnected nature of metabolic health, recognizing that insulin resistance affects sex hormone production, thyroid dysfunction impacts weight regulation, and chronic inflammation disrupts multiple endocrine pathways. Patients seeking medical weight loss receive comprehensive metabolic evaluation before beginning GLP-1 therapy, ensuring underlying thyroid disorders or hormone imbalances are identified and treated concurrently. Those pursuing hormone replacement undergo body composition analysis and metabolic assessment to optimize treatment outcomes. This systems-based approach, delivered through accessible telehealth consultations by a physician with specialized training in both internal medicine and obesity treatment, provides New Jersey residents with medically supervised functional medicine care grounded in evidence-based protocols and individualized to their specific metabolic profile.